XOMA Crosses Above Key Moving Average Level Friday, April 15, 1:21 PM ET, by Market News Video Staff In trading on Friday, shares of XOMA Ltd (XOMA) crossed above their 200 day moving ...
Bearish Two Hundred Day Moving Average Cross - BTX Wednesday, April 27, 11:41 AM ET, by Market News Video Staff In trading on Wednesday, shares of BioTime, Inc. (BTX) crossed below their 200 day moving ...
There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on August 19, Novavax's CEO, Stanley C. Erck, invested $16,380.00 into 13,000 shares of NVAX, for a cost per share of $1.26. Bargain hunters tend to pay particular attention to insider buys like this one, because presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money.
In trading on Tuesday, bargain hunters could buy shares of Novavax, Inc. (NASDAQ:NVAX) and achieve a cost basis 4.0% cheaper than Erck, with shares changing hands as low as $1.21 per share. Novavax, Inc. shares are currently trading down about 3.1% on the day. The chart below shows the one year performance of NVAX shares, versus its 200 day moving average:
Looking at the chart above, NVAX's low point in its 52 week range is $1.13 per share, with $3.50 as the 52 week high point — that compares with a last trade of $1.26. By comparison, below is a table showing the prices at which insider buying was recorded over the last six months:
Purchased
Insider
Title
Shares
Price/Share
Value
06/20/2011
Richard Douglas
Director
50,000
$2.04
$101,750.00
08/09/2011
Richard Douglas
Director
50,000
$1.20
$60,000.00
08/09/2011
Frederick W. Driscoll
VP, CFO & Treasurer
20,000
$1.18
$23,600.00
08/09/2011
John Trizzino
Snr. VP, Int & Govt Alliances
20,000
$1.19
$23,800.00
08/10/2011
Stanley C. Erck
President and CEO
50,000
$1.24
$62,000.00
08/19/2011
Stanley C. Erck
President and CEO
13,000
$1.26
$16,380.00
NVAX operates in the Biotechnology sector, among companies like Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) which is off about 1.9% today, and Dynavax Technologies Corp (NASDAQ:DVAX) trading relatively unchanged. Below is a three month price history chart comparing the stock performance of NVAX, versus LXRX and DVAX.
The ETF Channel Flexible Growth Investment Portfolio is designed to seek growth for investors —
anywhere and everywhere. The key to the program is our portfolio strategy allows us complete flexibility in terms of asset
allocation as there are no predetermined guidelines as to the level of stocks, bonds, cash, regions, countries, sectors,
commodities, or even asset classes in the portfolio! In short, this is a completely flexible portfolio designed to follow
the performance trail wherever it leads us.
This Article's Word Cloud:DVAXDirectorDouglasErckInvestmentLXRXNASDAQNVAXNovavaxPresidentRichardStanleyTreasurerValueaboutallowsassetbelowbuyingcashchartclassescompletelycostdesignedhuntersinsiderlastlikeonlyopenperformancepointportfolioreasonsharesharesshortshowingstockthattheirtherethistradingunchangedversusweekwhichwith
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.